NATCO declares an interim dividend of Rs. 2 per share Jan 27, 2010
 

Hyderabad based NATCO Pharma Limited had recommended a payment of Rs. 2 per equity share as an interim dividend for the financial year 2009-10.

 

The Board of Directors, which met at Hyderabad today, noted that the company has recorded a 11% growth in revenues on a year-on-year on basis (at Rs. 83 Crores in the third quarter of the current fiscal as against Rs. 75 Crores in the last year).  The net profit, after tax, on a stand-alone basis has also gone up by 7% on a year-on-year basis (from Rs. 1128 lakhs  to Rs. 1209 lakhs)  in the third quarter of the current year. 

 

On a consolidated basis, the cumulative earnings up to  end of December, 2009 amounted to Rs. 349 Crores (as against Rs. 331 Crores last year), while the cumulative profit after tax stood at Rs. 3368 lakhs (as against Rs. 3271 lakhs last year).

 

The Board has fixed Friday, the 8th February, 2010 as the record date for the payment of dividend

 

 

 
NATCO confirms filing of ANDA for Generic Revlimid 31/08/2010
NATCO denies speculative news 23/08/2010
NATCO reports increased earnings and profits 31/07/2010
NATCO launches Anastrazole in the USA 29/06/2010
NATCO records higher sales, profits 25/06/2010
NATCO launches BENDIT 07/04/2010
NATCO declares an interim dividend of Rs. 2 per share 27/01/2010
Press Release 09/01/2010
NATCO records increase in revenues, profits 29/10/2009
Natco’s note on anti-cancer drug Albupax 19/10/2009
NATCO Pharma launches Swine Flu medicine 18/09/2009
NATCO’s partner – Mylan’s – ANDA accepted for review of Glatiramer Acetate 14/09/2009
News | Careers | Privacy Policy
NATCO House, Road No: 2, Banjara Hills, Hyderabad - 500 033
Powered by www.sholay.in